Food avoidance is still considered the gold-standard treatment for food allergy (FA). However, recently it has been consolidating the theory that, where possible, the food intake might facilitate the induction of desensitization and tolerance, resulting more effective and safer -if we consider the possibility of accidental ingestion- than a strict avoidance diet [1].

Studies have shown short-term efficacy: namely theOIT-ability to induce desensitization (loss of responsiveness to food-antigen during continuous assumption of OIT-doses) [2–5]. Conversely, data are still insufficient and controversial regarding long-term efficacy: namely, the achievementof tolerance(configured when the offending food is removed from the diet and, if reintroduced, does not elicit any adversereaction) [2–5].

Recent data have shown that a key role in the induction of tolerance by OIT is played by a subgroup of regulatory T cells known as “induced T reg” (iTreg) [6, 7]. Epigenetic studies in vivo assessthatOIT determines hypomethylation of FOXP3 protein in specific antigen-iTreg only in individuals tolerant. Therefore, changes in the DNA of iTreg - specific antigen may predict the development of a state of clinical immune tolerance during OIT [8].

About safety, allergic reactions occurred in the majority of patients treated. They are primarily mild reactions, severe in about 4%; however, no threatening-life events nor death has been reported [9]. Frequency and severity of side effects seem reduced in protocols involving more gradual dose increases [1].

Several efforts have been made to perfect OIT: e.g.antigens with reduced allergenicity and adjuvants inducing faster immune responses of “protection”. Particularly promising is OIT associated with omalizumab, anti-IgE antibody, resulting safe and able to accelerate the desensitization compared to traditional protocols [10–12].

Further researches are needed in order to verify the degree of long-term safety as well as the long-term efficacy of OIT.

Given the interest and the celerity of development of this field of research in the recent years, we are confident in the near achievement of a personalized treatment, planned, safe and effective, to be used in clinical practice.

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.